Clinical trials: Optic Neuropathy
Normal Tension Glaucoma, Ocular Hypertension
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
The purpose of this study is to investigate IOP reduction efficacy of travoprost 0.004% ophthalmic solution (TRAVATAN Z®) in subjects with normal tension glaucoma.
- Trial name
- NCT01995136
- Testing
- Travoprost Ophthalmic Solution 0.004%
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Alcon Research
Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
The study objectives are to assess any changes in visual acuity and visual field observed following the administration of RPh201 during an overall treatment period of at least 13 consecutive weeks with an option to extended the…
- Trial name
- NCT02045212
- Testing
- RPh201
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Regenera Pharma Ltd
Neuromyelitis Optica
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
The aim of this study is to determine whether self-administered, at-home use of a transcutaneous electrical nerve stimulating device is an effective, acceptable and feasible method of relief from neuropathic pain among patients…
- Trial name
- NCT04614454
- Testing
- High Frequency Impulse Therapy
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Optic Neuritis
Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
Optic neuritis typically occurs in young (mean age, 32 years), female (77%) patients, and it presents as subacute monocular visual loss that develops over several days.
- Trial name
- NCT02939937
- Testing
- Phenytoin
- Where
- Iran
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
Neuromyelitis Optica Spectrum Disorder
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
The purpose of this study is to compare annual relapse rate, expanded disability status scale, and side effects of azathioprine and rituximab in patients with neuromyelitis optica spectrum disorder during a one year follow up…
- Trial name
- NCT03002038
- Testing
- Azathioprine, Rituximab
- Where
- Iran
- Volunteers
- 86 people
- Sponsor
- Isfahan University of Medical Sciences
Cataract, Retinal Edema
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
- Conditions
- Cataract, Retinal Edema, Inflammation
- Trial name
- QD (NCT01847638)
- Testing
- Prolensa (bromfenac 0.07%), Ilevro (nepafenac 0.3%)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Melissa Toyos
Anterior Ischemic Optic Neuropathy
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
- Trial name
- NCT00867815
- Testing
- Diagnostic procedures
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Wolfram Syndrome
I-Tracking Neurodegeneration in Early Wolfram Syndrome
Wolfram syndrome (WFS; OMIM #222300) is a rare autosomal recessive disease clinically defined in 1938 as the combination of childhood-onset insulin dependent diabetes, optic nerve atrophy, diabetes insipidus and deafness.
- Trial name
- I-TRACK (NCT03951298)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Washington University School of Medicine
Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy.
- Conditions
- Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma
- Trial name
- NCT00679354
- Testing
- cilengitide, laboratory biomarker analysis, pharmacological study
- Where
- 20 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
- Trial name
- NCT02200770
- Testing
- Inebilizumab
- Where
- 98 sites in United States, Australia and 23 more
- Volunteers
- 231 people
- Sponsor
- MedImmune LLC
Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back…
- Conditions
- Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
- Trial name
- NCT01553149
- Testing
- Lenalidomide, Pharmacological Study
- Where
- 126 sites in United States, Australia and 2 more
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Optic Neuritis
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
The main objective of the study is to determine whether glatiramer acetate 20 mg once daily reduces the amount of axonal loss in the optic nerve after a first event of acute optic neuritis compared to placebo patients and to…
- Trial name
- NCT00856635
- Testing
- Glatiramer Acetate
- Volunteers
- 44 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.